Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can changing clinic policies and training doctors reduce stigma around addiction?

NCT ID NCT06200012

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether combining a policy change with professional training can reduce stigma toward substance use in mental health clinics. Twelve providers from two sites participated. The goal was to see if the combined approach improves how often substance use is addressed and how many patients start medication for opioid or alcohol use disorders.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Multi-level stigma reduction intervention (educational training plus policy change)
What this could lead to
If successful, this could point toward effective ways to reduce stigma and improve access to substance use treatment in mental health clinics.
What could go wrong
This is a very small pilot study with only 12 providers, so results may not apply broadly. The intervention is behavioral and policy-based, so effects may be modest or hard to sustain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

12 people

The number who actually took part.

Started

Nov 2023

Finished

Feb 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Individuals must meet all of the inclusion criteria in order to be eligible to participate in the study. 1. Site inclusion: * The sites will be selected using convenience sampling. * The inclusion criterion will be sites with at least 4 providers. 2. Provider inclusion: * Providers at participating sites will also be recruited using convenience sampling. * Any psychiatrists or psychiatric NPs are eligible to participate as long as they are employed at the participating LSH site. 3. Patient EHR inclusion: * All new patients entering mental health services during the 3-months prior and 3- months after the intervention will be included in the EHR data sample to assess whether substance use was addressed during their first visit and subsequent 3-month retention in care. * Existing and new patients with alcohol use disorder (AUD)/opioid use disorder (OUD) will be identified through the EHR to assess pharmacotherapy initiation. 4. Patient survey inclusion: * Half of the survey sample (n=20) will include patients without a substance use disorder (SUD) documented in their chart at the time of data collection * The other half of the survey sample (n=20) will include patients who do have an ICD-10 code for SUD in their chart. * Patient stratification rationale: the intention is to compare experiences and perceptions of stigma among patients who have SUD noted in their EHR and those who do not. This is also to assess stigma among patients who may not have their substance use addressed during a MH visit but who have substance use related health risks and substance use disorders (assessed through the ASSIST questionnaire). Exclusion Criteria: All individuals meeting any of the exclusion criteria will be excluded from study participation. 1. Provider exclusion: * Providers may be excluded if they were not employed by LSH and seeing patients for the past three months at the time of enrollment. 2. Patient exclusion: * Patients may be excluded from the SUD-stratified portion of the survey sample if their SUD diagnosis is only for a tobacco use disorder. * Patients may also be excluded if they are unable or unwilling to give written informed consent. * Patients who are currently in jail, prison or other overnight facility as required by court of law or have pending legal action that could prevent participation in study activities will also be excluded.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alcohol use disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • LifeStance Health

    Albuquerque, New Mexico, 87106, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.